Histogenics develops restorative cell therapies for orthopedic pain relief.
Here are three things to know:
1. Histogenics' restorative cell therapy platform is designed to enhance the autologous cartilage repair process to produce functional living cartilage at the time of treatment.
2. The company's first RCT product candidate, NeoCart, is intended to rebuild a patient's own knee cartilage and may delay or prevent osteoarthritis.
3. Adam Gridley serves as president and CEO of Histogenics. He has more than 20 years of experience in the medical device, biotechnology and pharmaceutical industries.